Sacubitril/valsartan vs. valsartan initiation in patients with heart failure and EF>40% who are naive to renin-angiotensin-system inhibitors: Insights from PARAGLIDE-HF

Back

HFA Premium Access

Sacubitril/valsartan vs. valsartan initiation in patients with heart failure and EF>40% who are naive to renin-angiotensin-system inhibitors: Insights from PARAGLIDE-HF

Session: Chronic heart failure - treatment 7

Topic: Pharmacotherapy

Speaker: Doctor R. Mentz (Durham, US)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Robert Mentz

Duke University Medical Center, Durham (United States of America)

10 presentations

0 follower

7 more presentations in this session

A prospective interventional randomized study to assess efficacy of angiotensin receptor neprilysin inhibitor in right ventricular systolic dysfunction with normal left ventricular systolic function.

Speaker: Doctor R. Mathur (Jodhpur, IN)

Optimization of pharmacological treatment of heart failure in patients followed in specialized HF units in Spain.

Speaker: Doctor R. Gonzalez-Manzanares (Cordoba, ES)

Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.

Speaker: Doctor R. Carvalho (Lisbon, PT)

Characteristics of patients initiating dapagliflozin for heart failure with reduced ejection fraction in Italian clinical practice: a 6-month interim analysis of EVOLUTION-HF Italy

Speaker: Associate Professor P. Ameri (Genova, IT)

Asymptomatic versus symptomatic hypotension in HFrEF: Findings with sacubitril/valsartan in PARADIGM-HF

Speaker: Doctor S. Matsumoto (Tokyo, JP)

Access the full session

Chronic heart failure - treatment 7

Speakers: Doctor R. Mentz, Doctor R. Mathur, Doctor R. Gonzalez-Manzanares, Doctor R. Carvalho, Associate Professor P. Ameri...

Access

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources